Inventiva News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.01.20	Inventiva admitted to the SRD “Long only” on the regulated market of Euronext Paris (GlobeNewswire)
18.12.19	Inventiva announces positive results from Phase IIa clinical study with odiparcil in mucopolysaccharidosis type VI (GlobeNewswire)
03.12.19	Inventiva receives a €3.5 m milestone payment from AbbVie (GlobeNewswire)
13.11.19	Q3 2019 financial information and update on the partnership with Boehringer Ingelheim (GlobeNewswire)
12.11.19	Inventiva to present at the Jefferies 2019 London Healthcare Conference (GlobeNewswire)
16.10.19	Inventiva participera à la « H.C. Wainwright 3rd Annual NASH Investor Conference » et au « Gilbert Dupont NASH Day » (GlobeNewswire)
30.09.19	Inventiva completes a capital increase of € 625,000 subscribed by Sofinnova Partners through Sofinnova Crossover I Fund (GlobeNewswire)
26.09.19	Inventiva receives FDA Fast Track designation for lead asset lanifibranor in NASH (GlobeNewswire)
25.09.19	Inventiva: H1 2019 financial results and corporate business update (GlobeNewswire)
19.09.19	Inventiva completes a capital increase of € 8.2 million subscribed by leading US and European biotech investors (GlobeNewswire)
10.09.19	Inventiva announces the positive recommendation of the 4th and last DSMB of the Phase IIb clinical study with lanifibranor in NASH (GlobeNewswire)
04.09.19	Inventiva achieves a major milestone by completing patient recruitment for its Phase IIb clinical study with lanifibranor in NASH (GlobeNewswire)
02.09.19	Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults (GlobeNewswire)
28.08.19	Inventiva secures a new European patent strengthening and extending the protection of its lead product candidate lanifibranor (GlobeNewswire)
26.08.19	Inventiva - New promising results on lanifibranor to be presented at The Liver Meeting® 2019 (GlobeNewswire)
30.07.19	Inventiva - H1 2019 Financial Information and Corporate Business Update (GlobeNewswire)
09.07.19	Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux (GlobeNewswire)
13.06.19	Inventiva announces the creation of its Scientific Advisory Board (GlobeNewswire)
11.06.19	Inventiva Announces End of Patient Recruitment for its Phase IIa Trial in the Treatment of MPS VI (GlobeNewswire)
29.05.19	Nawal Ouzren and Heinz Maeusli appointed to Inventiva’s Board of Directors (GlobeNewswire)
24.05.19	Inventiva to Present at the Jefferies 2019 Healthcare Conference (GlobeNewswire)
23.05.19	Repeat: Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH (GlobeNewswire)
23.05.19	Inventiva announces that FDA lifts target class clinical hold which allows long-term clinical studies with lanifibranor in NASH (GlobeNewswire)
15.05.19	Q1 2019 Financial Information and Corporate Business Update (GlobeNewswire)
23.04.19	Inventiva to present new results of its YAP-TEAD oncology program at the AACR Special Conference on The Hippo Pathway (GlobeNewswire)
05.03.19	INVENTIVA : The FDA Grants Rare Pediatric Disease Designation to Odiparcil for the Treatment of MPS VI (GlobeNewswire)
27.02.19	INVENTIVA: 2018 Full-Year Results : Important Progress in R&D Portfolio and Solid Cash Position (GlobeNewswire)
21.02.19	Inventiva announces further progress achieved in the clinical development of lanifibranor for the treatment of NASH (GlobeNewswire)
04.02.19	INVENTIVA : New results on lanifibranor to be presented at the International Liver Congress 2019 (GlobeNewswire)
10.12.18	Inventiva invited to present at the 37th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
13.11.18	Inventiva: 2018 third quarter financial update (GlobeNewswire)
07.11.18	Inventiva Announces Poster Presentation on Its YAP/TEAD Inhibitor Program at the EORTC-NCI-AACR Symposium in Dublin (GlobeNewswire)
17.10.18	Inventiva announces two appointments to its management team ahead of future key development milestones (GlobeNewswire)
15.10.18	Inventiva Announces Last Visit by Last Patient in its Phase IIb SSc Trial and Second Positive DSMB Review in its Phase IIb NASH Trial with Lanifibranor (GlobeNewswire)
12.10.18	INVENTIVA to Participate in the "ROTH Battle of the NASH Thrones Investor Conference" (GlobeNewswire)
10.10.18	Inventiva Announces Two Poster Presentations at the American College of Rheumatology Conference (GlobeNewswire)
27.09.18	Inventiva: First-half 2018 financial results and business update (GlobeNewswire)
24.09.18	INVENTIVA : Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment (GlobeNewswire)
30.08.18	INVENTIVA advances in the development of lanifibranor with the achievement of three key milestones (GlobeNewswire)
23.08.18	Inventiva S.A.: Sale of Shares (GlobeNewswire)
23.08.18	Inventiva S.A.: Sale of Shares (GlobeNewswire)
22.08.18	Inventiva announces that it has been informed of the modification of the call option agreement concluded by BVF Partners L.P. (GlobeNewswire)
13.08.18	Inventiva's lanifibranor found to have good safety profile following first assessment of carcinogenicity studies' results (GlobeNewswire)
19.07.18	Inventiva Reports First-half 2018 Financial Results and Provides a Corporate Update (GlobeNewswire)
10.07.18	Inventiva Announces Positive DSMB Reviews in both NASH and Systemic Sclerosis Phase IIb Trials with Lanifibranor (GlobeNewswire)
20.06.18	INVENTIVA : FDA Approval of an Investigator Initiated IND Application to Conduct Phase II Study of Lanifibranor in Type 2 Diabetic Patients with Non-Alcoholic Fatty Liver Disease (GlobeNewswire)
04.04.18	INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes (GlobeNewswire)
07.03.18	INVENTIVA : 2017 Full Year Results - Major progress achieved in clinical development and strong cash position (GlobeNewswire)
26.02.18	Inventiva announces positive outcomes of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients (GlobeNewswire)
07.11.17	Inventiva: Third-Quarter 2017 Financial Information (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Inventiva SA act ord

Aktien Top/Flop

Meistgelesene Nachrichten